Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07592520 · ClinicalTrials.gov registry record · Phase 4
Flush, Lyse, Operate
A Phase 4 study, sponsored by Dartmouth-Hitchcock Medical Center.
- Not yet
- Registry status
- Phase 4
- Development phase
- 30
- Enrollment target
NCT07592520: Clinical Trial Phase 4 study, sponsored by Dartmouth-Hitchcock Medical Center.
NCT07592520 is a Phase 4 study that has not yet begun recruiting, run by Dartmouth-Hitchcock Medical Center. The registered enrollment target is 30 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (94% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07592520, a Phase 4 study, has not yet begun recruiting, sponsored by Dartmouth-Hitchcock Medical Center.
- NOT YET RECRUITING
- Registry status
- Phase 4
- Development phase
- 30 participants
- Enrollment target
Study Summary
The goal of this observational study is to learn if saline results in improvement for patients with infection of their plerual space. The main question it aims to answer is: What is the time to chest tube removal? Do these patients after need to escalate to fibrinolytics? Do these patients after need to escalate to surgery? Participants will: * Receive receive saline into their pleural space through an existing chest tube * If they fail to improve, which will be determined by fluid size after treatment or signs of persistent infection, they will receive fibrynolytics through an existing chest tube * If they fail to improve, which will be determined by fluid size after treatment or signs of persistent infection, they will be referred to surgery.
Primary Outcome
measuring the length of time from chest tube insertion to removal
Interventions
- DRUG Intrapleural Saline with possible escalation to intraplerual alteplase and dornase.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2026-04 |
| Est. Completion | 2027-04 |
| Phase | Phase 4 |
What is known before NCT07592520 opens enrollment
NCT07592520 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (94% lower).
The record links to 0 conditions, and to 1 intervention - of which Intrapleural Saline with possible escalation to intraplerual alteplase and dornase. is the first listed.
NCT07592520 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07592520 about?
NCT07592520 is a clinical study titled "Flush, Lyse, Operate". The goal of this observational study is to learn if saline results in improvement for patients with infection of their plerual space. The main question it aims to answer is: What is the time to chest tube removal? Do these patients after need to escalate to fibrinolytics? Do these patients after ne...
What is the current status of trial NCT07592520?
This trial is currently not yet recruiting. It is a Phase 4 study. The enrollment target is 30 participants. The study started on 2026-04. Estimated completion is 2027-04.
What interventions are being tested in trial NCT07592520?
The interventions under investigation include: Intrapleural Saline with possible escalation to intraplerual alteplase and dornase. (DRUG).
Who is sponsoring clinical trial NCT07592520?
This trial is sponsored by Dartmouth-Hitchcock Medical Center, which has 427 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07592520's enrollment target sits among peer trials
30 1552nd of 2000 higher than 367 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia